(2R)-Amino(3,5-dinitrophenyl)acetic acid

Names

[ Name ]:
(2R)-Amino(3,5-dinitrophenyl)acetic acid

[Synonym ]:
(2R)-2-[(3,5-dinitrobenzoyl)amino]-2-phenylacetic acid
(2R)-Amino(3,5-dinitrophenyl)acetic acid
Benzeneacetic acid, α-amino-3,5-dinitro-, (αR)-
MFCD00010134

Chemical & Physical Properties

[ Density]:
1.7±0.1 g/cm3

[ Boiling Point ]:
421.4±45.0 °C at 760 mmHg

[ Melting Point ]:
217-218 °C (dec.)

[ Molecular Formula ]:
C₁₅H₁₁N₃O₇

[ Molecular Weight ]:
241.158

[ Flash Point ]:
208.6±28.7 °C

[ Exact Mass ]:
241.033478

[ PSA ]:
158.04000

[ LogP ]:
0.34

[ Vapour Pressure ]:
0.0±1.1 mmHg at 25°C

[ Index of Refraction ]:
1.667

MSDS

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Safety Phrases ]:
S22-S24/25

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ HS Code ]:
2924299090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

D-2-Phenylglycine
3,5-Dinitrobenzoyl chloride
n-3-5-dinitrobenzoyl-dl-phenylglycine
2-Phenylglycine

DownStream

Customs

[ HS Code ]: 2924299090

[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Articles

A screening method for chiral selectors that does not require covalent attachment.

J. Am. Chem. Soc. 128(7) , 2208-9, (2006)

A high-throughput screening protocol is proposed for chiral selector discovery. It is modeled after the protocol for biological screening of candidate drugs from chemical libraries. The procedure work...

Resolution of enantiomers of 19-hydroxyeicosatetraenoate and 18-hydroxyeicosatetraenoate by chiral phase high-performance liquid chromatography of naphthoyl ester derivatives.

J. Chromatogr. A. 526(2) , 525-9, (1990)

QSAR of matrix metalloproteinase inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates using LFER model.

Drug Des. Discov. 17(4) , 315-23, (2001)

QSAR analyses of matrix metalloproteinase (MMP) inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates, recently reported by Scozzafava and Supuran, have been attempted using l...

(2R)-Amino(4-hydroxy-3,5-diiodophenyl)acetic acid
(R)-2-(3,5-Difluorophenyl)-2-hydroxyacetic acid
(4-amino-3,5-dichlorophenyl)acetic acid ethyl ester
(4-Amino-3,5-diiodo-phenyl)-acetic acid ethyl ester
(4-Amino-3,5-dibromo-phenyl)-acetic acid ethyl ester
(4-Amino-3,5-dibromo-phenyl)-acetic acid
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
N-(3-chloro-4-methylphenyl)-4-oxo-1-phenyl-1,4-dihydropyridazine-3-carboxamide
(4-Methyl-tetrahydro-furan-2-yl)-methanol
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
2-(1-((4-chlorophenyl)sulfonyl)piperidin-2-yl)-N-(2,4-dimethylphenyl)acetamide
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
tert-Butyl-DL-alanine